Bioequivalence Study of Dutasteride Capsules-An Evaluation of the Bioequivalence of Dutasteride Capsule Manufactured at GSK Compared to Dutasteride Capsule Manufactured at Catalent in Healthy Japanese Male Subjects

Trial Profile

Bioequivalence Study of Dutasteride Capsules-An Evaluation of the Bioequivalence of Dutasteride Capsule Manufactured at GSK Compared to Dutasteride Capsule Manufactured at Catalent in Healthy Japanese Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jan 2018 Primary endpoint (Maximal measured plasma concentration (Cmax) of dutasteride test product and reference product) has not been met, according to the results published in the Clinical Pharmacology in Drug Development
    • 01 Jan 2018 Primary endpoint (Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t) of dutasteride test product and reference product) has been met, according to the results published in the Clinical Pharmacology in Drug Development
    • 01 Jan 2018 Results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top